Boehringer Ingelheim

Boehringer Ingelheim Middle East & North Africa (Scientific Office) FZ-LLC

To,
Whom It May Concern

Boehringer Ingelheim
Middle East & North Africa
(Scientific Office) FZ-LLC

21 January, 2015

Dr. Shekhar Gothoskar
P.O. Box 505123, Dubai
United Arab Emirates
Telephone +971-4-4230450
Telefax +971-4-4233637

Registered under:
Dubai Health Care City
Licence Number: 00403
Building 49, First Floor

Direct Healthcare Professional Communication on restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing (TELMISARTAN, TELMISARTAN + HYDROCHLOROTHIAZIDE):

(MICARDIS & MICARDIS PLUS **tablets)**

Dear Healthcare Professional,

Boehringer Ingelheim would like to inform you about restrictions on combining different classes of medicines that act on the renin-angiotensin aldosterone system (RAAS), a hormone system that controls blood pressure and the volume of fluids in the body. This group of medicines (called RAAS-acting agents) has three main classes: angiotensin-receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACE-inhibitors) and direct renin inhibitors such as aliskiren. Combination of medicines from any two of these classes should not be used and, in particular, in patients with diabetes mellitus or renal impairment.

Information on the safety Concern

- Combination therapy of direct renin inhibitors such as aliskiren with ACEI or ARB may cause an increased risk of hyperkalemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with diabetes mellitus or renal impairment.

- Combination therapy of ACEI and ARB drugs may cause an increased risk of hyperkalemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with diabetes mellitus or renal impairment.

Boehringer Ingelheim

- If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.

The information in this letter has been approved by the Saudi Food and Drug Authority.

The Summary of Products Characteristics (SPC) and patient leaflet of (Micardis & Micardis Plus tablets) in Saudi Arabia will be updated shortly to reinforce the safety of treated patients.

Call for reporting
As a reminder, there is a need to report any suspected adverse reactions to the National Pharmacovigilance and Drug Safety Center (NPC):

By email: npc.drug@sfda.gov.sa
Or by fax: +966 11 2057662
Or by online: https://ade.sfda.gov.sa/

Pharmacovigilance department in Boehringer Ingelheim Saudi Arabia

- Fax: 00966-11-4601755
- PV_local_Saudi_Arabia@boehringer-ingelheim.com

Dr. Shekahr Gothoskar
Medical Affairs Manager
Boehringer Ingelheim MENA